UF Health Cancer Center at the AACR Annual Meeting 2022


The American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer. Through its programs and services, the AACR fosters research in cancer and related biomedical science, accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer, promotes science education and training, and advances the understanding of cancer etiology, prevention, diagnosis and treatment throughout the world.

The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research — from population science and prevention to cancer biology, translational and clinical studies to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world.

The AACR Annual Meeting 2022 is scheduled to take place April 8 – 13, 2022 at the Ernest N. Morial Convention Center in New Orleans, La. The online planner displays the sessions, presentations and abstracts of the virtual AACR Annual Meeting.

UF Health Cancer Center Member Presentation Schedule

April 8, 2022

OPO.CL03.01 – Clinical Research in Special Populations
5181 – The association of metformin dose and cancer survival in older adults with advanced cancer: SEER-Medicare analysis
Time: 12 p.m. – 1 p.m.
Lisa Scarton, Ara Jo, Zhigang Xie, LaToya J. O’Neal, Juan M. P. Pena, Thomas J. George, Jiang Bian

Session OPO.ET01.01 – Drug Discovery
5313 – A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers
Time: 12 p.m. – 1 p.m.
Sajid Khan, Janet Wiegand, Peiyi Zhang, Wanyi Hu, Dinesh Thummuri, Vivekananda Budamagunta, Nan Hua, Lingtao Jin, Carmen J. Allegra, Edmund S. Kopetz, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng, Daohong Zhou

Session OPO.ET03.01 – Drug Resistance
5357 – mTOR kinase inhibitor AZD8055 reverses acquired rapamycin resistance in prostate cancer cells
Time: 12 p.m. – 1 p.m.
Yao Dai, Dietmar Siemann

Session OPO.ET09.01 – Preclinical Radiotherapeutics
5431 – FGF7 peptide (FGF7p) mimetic mitigates urothelial injury from cyclophosphamide or radiation
Time: 12 p.m. – 1 p.m.
Sridhar Narla, Lori P. RiceDavid Ostrov, Steven G. Swarts, Dietmar W. Siemann, Carlton M. Bates

Session OPO.MCB02.01 – Cell Death
5654 – Degradation of Bcl-xL by DT2216 is lethal to T-cell acute lymphoblastic leukemia
Time: 12 p.m. – 1 p.m.
Arunima S. Jaiswal, Elizabeth Williamson, Robert A. Hromas, Daohong Zhou

Session OPO.MCB10.01 – microRNAs and Other Noncoding RNAs
5821 – Enhanced tumorigenesis in a novel miR-216a knockout/KPC mouse model of pancreatic cancer
Time: 12 p.m. – 1 p.m.
Andrew A. Brock, Katherine Powell, Thomas D. Schmittgen, Lorenzo F. Sempere

Session OPO.BCS01.01 – Bioinformatics and Computational Biology
5030 – Intra-patient tumor evolution analysis in dogs with many mammary tumors identifies signatures of tumor aggression in early-stage breast cancers
Time: 12 p.m. – 1 p.m.
Kiley Graim

April 10, 2022

Session PO.MCB11.02 – Cellular Stress Responses 2: Senescence and Unfolded Protein Response
138 / 4 – NIR fluorescent probes for senescence imaging via tunable in situ labeling
Time: 1:30 p.m. – 5 p.m.
Zixin Chen, Yuzhao Zhang, Seyedehalaleh Anvar, Chang-hung Wu, Jun Liu, Joyce Z. Jiang, Lina Cui

April 11, 2022

Session PO.PR01.02 – Preclinical Prevention, Early Detection, and Interception 2
714 / 9 – Weight changes between one year before and following breast cancer diagnosis in relation to mTOR protein expression in tumor tissues in the Women’s Circle of Health Study
Time: 9:30 a.m. – 12:30 p.m.
Mmadili N. Ilozumba, Angela R. Omilian, Song Yao, Weizhou Zhang, Susmita Datta, Warren Davis, Chi-Chen Hong, Elisa V. Bandera, Thaer Khoury, Christine B. Ambrosone, Ting-Yuan David Cheng

Session PO.TB01.05 – Cell Line and Animal Models
1622 / 14 – Signaling of cyclin-dependent kinase 12 (CDK12) in prostate cancer cell lines
Time: 1:30 p.m. – 5 p.m.
Victor Chalfant, Carlos Riveros, Sanjeev Shukla, Teruko Osumi, K Balaji

April 12, 2022

Session LBPO.MCB02 – Late-Breaking Research: Molecular/Cellular Biology and Genetics 2
LB138 / 14 – DAXX interacts with sterol regulatory element-binding proteins (SREBPs) to promote oncogenic lipogenesis and tumorigenesis in triple-negative breast cancer
Time: 9 a.m. – 12:30 p.m.
Iqbal Mahmud, Guimei Tian, Tarun Hutchison, Brandon Kim, Daiqing Liao

Session PO.CH02.01 – Structural and Chemical Biology
2925 / 10 – Expanding the library of small molecule imaging probes for heparanase
Time: 9 a.m. – 12:30 p.m.
Kelton Schleyer, Jun Liu, Zhishen Wang, Hua Guo, Lina Cui

Session PO.ET06.04 – Signaling Pathway Inhibitors
2678 / 21 – LLL12B, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer cells
Time: 9 a.m. – 12:30 p.m.
Li Pan, Xiang Chen, Feyruz V. Rassool, Chenglong Li, Jiayuh Lin

Session PO.PR02.02 – Premalignant Lesions, Intervention, and Health Disparities
2213 / 13 – Generating a collection of isogenic lung adenocarcinoma cell lines to study RAS gene activation in black Americans
Time: 9 a.m. – 12:30 a.m.
Pablo E. Puente, Chunli Yan, Matthew Gregory, Nadine L. Belony, Nazarius Lamango, Yong Huang, Ite A. Offringa

Session PO.PS01.02 – Biomarkers of Endogenous or Exogenous Exposures, Early Detection, and Biologic Effects
2265 / 19 – HCV seroprevalence and RNA detection rates across Florida, 2015-2018
Time: 9 a.m. – 12:30 p.m.
Brittney L. Dickey, Anna E. Coghill, Richard R. Reich, Julie Rathwell, Susan T. Vadaparampil, Shannon M. Christy, Richard Roetzheim, Elizabeth Shenkman, Anna R. Giuliano

Session APRV01 – The Role of Bacterial Infection in Cancer
Taking a deep dive into the molecular mechanism of bacteria-induced carcinogenesis
Time: 11:10 a.m. – 11:30 p.m.
Christian Jobin

Session LBPO.PSPR01 – Late-Breaking Research: Population Sciences / Prevention, Early Detection, and Interception
LB167 / 11 – Functional extracellular vesicle profiling with nanochips for cancer diagnosis and monitoring
Time: 1:30 p.m. – 5 p.m.
Yong Zeng, Shibo Chen, Yunjie Wen, Liang Xu

Session PO.ET03.06 – Drug Resistance and Reversal of Resistance
3252 / 21 – Tumor treating fields suppression of ciliogenesis enhances temozolomide toxicity
Time: 1:30 p.m. – 5 p.m.
Ping Shi, Jia Tian, Brittany Ulm, Julianne Mallinger, Habibeh Khoshbouei, Loic Deleyrolle, Matthew Sarkisian

Session PO.IM02.19 – Modifiers of the Tumor Microenvironment
3548 / 18 – Role of the cancer cell proteome and tumor microenvironment in the hyperprogression (HP) phenotype response to immune checkpoint blockade
Time: 1:30 p.m. – 5 p.m.
Andrew George, Ilyas Sahin, Shengliang Zhang, Wafik S. El-Deiry

Session PO.MCB01.05 – GTPase and Ubiquitin Signaling
2989 / 18 – FAP facilitates ovary tumorigenesis through the NF-κB/survivin funcational axis
Time: 1:30 p.m. – 5 p.m.
Bin Li, Shuang Huang

Session PO.MCB02.01 – Non-apoptotic Cell Death / Autophagy
3005 / 12 – Inflammasome-independent pyroptosis mediates DHA-led ovarian cancer cell death
Time: 1:30 p.m. – 5 p.m.
Ozlem Calbay, Shuang Huang

Session PO.PS01.03 – Survivorship and Prognosis Biomarkers
3219 / 6 – Changes and intra-individual reliability in computed tomography image-assessed adiposity and skeletal muscles areas after breast cancer surgery
Time: 1:30 p.m. – 5 p.m.
Livingstone Aduse-Poku, Dheeraj Gopireddy, Mauricio Henandez, Chandana Lall, Joel Divaker, Sara Falzarano, Shahla Masood, Weizhou Zhang, Susmita Datta, Jiang Bian, Ting-Yuan David Cheng

Session PO.TB06.07 – Microbiome
3051 / 9 – Commensal microbiota, host DNA methylation and gene expression: A pilot study in colorectal adenomas
Time: 1:30 p.m. – 5 p.m.
Yaohua Yang, Jirong Long, Martha J. Shrubsole, Qiuyin Cai, Zhiguo Zhao, Fei Ye, Zhigang Li, Xingyi Guo, Bingshan Li, Seth R. Bordenstein, Ken S. Lau, Harvey J. Murff, Reid M. Ness, Robert J. Coffey, Wei Zheng

April 13, 2022

Session PO.ET05.01 – Molecular Pharmacology
4038 / 17 – Study of therapeutic effects of polyisoprenylated cysteinyl amide inhibitors on lung cancer cells of black patients using 3D-Printed alveolar model
Time: 9 a.m. – 12:30 p.m.
Nadine Belony, Bing Ren, Phuc Pham, Matthew Gregory, Pablo E. Puente, Nazarius S. Lamango, Ite A. Offringa, Yong Huang

Session PO.ET06.05 – New Chemotherapy Agents
4055 / 9 – First in class multifunctional non classical antifolates inhibits thymidylate synthase and extends survival in pancreatic cancer model
Time: 9 a.m. – 12:30 p.m.
Maria V. Guijarro, Patrick C. Kellish, Peter E. Dib, Nicholas G. Paciaroni, Akbar Nawab, Jacob Andring, Lidia Kulemina, Nicholas V. Borrero, Carlos Modenutti, Richard L. Bennett II, Daniil Shabashvili, Jonathan D. Licht, Robert McKenna, Adrian Roitberg, Robert W. Huigens III, Frederic J. Kaye, Maria Zajac-Kaye

Session PO.MCB05.04 – Chromatin Modifiers: Mutations and Novel Therapeutics
3719 / 3 – Loss of Kmt2c, of the COMPASS-like complex, cooperates with oncogenic signaling in cancer
Time: 9 a.m. – 12:30 p.m.
Gabriel Prado, Richard L. Bennett, Jonathan D. Licht

Session PO.PS01.04 – Cancer Health Disparities
3682 / 21 – Quadruple negative breast tumors in African American women express factors associated with worse prognosiscompared to triple negative tumors
Time: 9 a.m. – 12:30 p.m.
Oluwadamilola Oladeru, Yasmine Kanaan, Tammy Naab, Luisel J. Ricks-Santi

Session PO.TB08.01 – Therapeutic Targets and Drug Resistance in Pediatric Cancers
3888 / 4 – Targeting Bcl-xL in fibrolamellar hepatocellular carcinoma
TIme: 9 a.m. – 12:30 p.m.
Bassem Shebl, Gadi Lalazar, Denise Ng, Tova Finkelstein, Guangrong Zheng, Peiyi Zhang, Carly Rosemore, Michael Ortiz, Daohong Zhou, Sanford Simon, Philip Coffino